Aligos receives Nasdaq notice for Audit Committee noncompliance; cure period to Nov 2024

Aligos Therapeutics, Inc.

Jack Nielsen resigned from Board and Audit Committee on May 21, 2024, causing noncompliance with Rule 5605.
Nasdaq granted cure period until Nov 18, 2024, as next annual meeting is June 27, 2024.
Company plans to appoint a third independent director to the Audit Committee before the cure deadline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.